PF-429242

PF429242 is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM[1].

Product Specifications

CAS Number

[947303-87-9]

UNSPSC

12352005

Hazard Statement

H315-H319-H335-H410

Target

Fatty Acid Synthase (FASN) ; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/pf-429242.html

Solubility

10 mM in DMSO

Smiles

O=C(N(CCC1=CC=CC=C1OC)[C@H]2CNCC2)C3=CC=C(CN(CC)CC)C=C3

Molecular Formula

C25H35N3O2

Molecular Weight

409.56

Precautions

P261-P264-P271-P273-P280-P302+P352-P304+P340-P362+P364-P391-P405-P501

References & Citations

[1]Hawkins JL, et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther. 2008 Sep;326 (3) :801-8.|[2]Uchida L, et al. Suppressive Effects of the Site 1 Protease (S1P) Inhibitor, PF-429242, on Dengue Virus Propagation. Viruses. 2016 Feb 10;8 (2) . pii: E46.|[3]Urata S, et al. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol. 2011 Jan;85 (2) :795-803.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

J Neurosci Res. 2025 Jun;103 (6) :e70054.|Autophagy. 2021 Jul;17 (7) :1592-1613.|Cell Death Differ. 2021 Jun;28 (6) :2001-2018.|Cell Death Dis. 2025 Jul 11;16 (1) :512.|Hypertension. 2021 Feb;77 (2) :405-416.|Immunity. 2018 Nov 20;49 (5) :842-856.e7. |JCI Insight. 2019 Apr 4;4 (7) . pii: 124174. |Nature. 2023 Apr;616 (7956) :348-356.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.